THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

Similar documents
THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF)

A Quick Guide to the. I507del. Mutation CFTR SCIENCE

A Quick Guide to the G A. Mutation CFTR SCIENCE

A Quick Guide to the. CFTRdele2,3. Mutation CFTR SCIENCE

A Quick Guide to the 621+1G T. Mutation CFTR SCIENCE

CYSTIC FIBROSIS (CF) COMPLICATIONS BEYOND THE LUNGS. A Resource for the CF Center Care Team

"Management and Treatment of Patients with Cystic fibrosis (CF)

Symdeko. Symdeko (tezacaftor and ivacaftor) Description

Kalydeco. Kalydeco (ivacaftor) Description

CYSTIC FIBROSIS (CF): THE CHALLENGE OF EARLY, SYSTEMIC PROGRESSION

Transformational Treatments. PRESTON W. CAMPBELL, III, M.D. Executive Vice President for Medical Affairs

Evaluation of Patients with Diffuse Bronchiectasis

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

UNDERSTANDING THE EARLY, SYSTEMIC PROGRESSION OF CYSTIC FIBROSIS (CF) A Resource for the CF Center Care Team

Respiratory Pharmacology: Treatment of Cystic Fibrosis

Cystic Fibrosis Foundation Patient Registry 2013

Medical Policy An independent licensee of the Blue Cross Blue Shield Association

UNDERSTANDING THE EARLY, SYSTEMIC PROGRESSION OF CYSTIC FIBROSIS (CF)

Pharmacy Policy Bulletin

GENETIC TESTING: IN WHOM AND WHEN

Orkambi. Orkambi (lumacaftor/ivacaftor) Description

A Genetic Approach to the Treatment of Cystic Fibrosis

Cystic Fibrosis: Progress in Treatment Management. Patrick A. Flume, M.D. Medical University of South Carolina

The Future of CF Therapy

Cystic Fibrosis the future

Cystic fibrosis (CF) is the most frequent. Ivacaftor treatment in patients with cystic REVIEW. Isabelle Sermet-Gaudelus

Case Study What is the Relationship Between the Cell Membrane and Cystic Fibrosis?

Cost-effectiveness of Ivacaftor (Kalydeco ) for the treatment of cystic fibrosis in patients age 6 years and older who have the G551D mutation

Pharmacogenomics in Rare Diseases: Development Strategy for Ivacaftor as a Therapy for Cystic Fibrosis

Recently, the cystic fibrosis (CF) community celebrated the 25th

6.2.1 Exocrine pancreatic insufficiency

Application to be an additional provider for existing test on the NHS Directory of Molecular Genetic Testing Additional Provider form

PA Update: Oral Cystic Fibrosis Modulators

Atypical cystic fibrosis: from the genetic causes to current and future treatments

A Case of Cystic Fibrosis

What is the inheritance pattern (e.g., autosomal, sex-linked, dominant, recessive, etc.)?

Briefing Document. FDA Pulmonary - Allergy Drugs Advisory Committee

CYSTIC FIBROSIS OBJECTIVES NO CONFLICT OF INTEREST TO DISCLOSE

Supplementary appendix

Goals Basic defect Pathophysiology Clinical i l signs and symptoms Therapy

Drug Use Criteria: Ivacaftor (Kalydeco ) and Lumacaftor/Ivacaftor (Orkambi )

A review of Cystic Fibrosis

Evening Case studies, Tuesday April 30, Vijay L. Grey McMaster University

CFTR Genotype as a Predictor of Prognosis in Cystic Fibrosis*

Disclosures. Advances in the Management of Cystic Fibrosis: A Closer Look at the Roles of CFTR Modulation Therapy 10/28/2016

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

Title: Lack of correlation between pulmonary disease and CFTR dysfunction in cystic fibrosis -- the case of 3791delC

IVACAFTOR THE ISRAELI EXPERIENCE ADI DAGAN MD THE ISRAELI CF CENTER SHEBA MEDICAL CENTER, TEL-HASHOMER

Pediatrics Grand Rounds 13 November University of Texas Health Science Center at San Antonio. Learning Objectives

Brand Name: Kalydeco. Generic: ivacaftor. Manufacturer 1 : Vertex Pharmaceuticals Incorporated

Lab Activity Report: Mendelian Genetics - Genetic Disorders

Key Points: References: Canadian data from the Canadian Cystic Fibrosis Registry 2015 Annual Report normal

Pediatrics Grand Rounds 18 Sept University of Texas Health Science Center. + Disclosure. + Learning Objectives.

At-A-Glance report 2014

North American Cystic Fibrosis Conference 27 October Noreen R Henig, MD Chief Development Officer ProQR Therapeutics

At-A-Glance report 2013

Cystic Fibrosis Diagnosis and Treatment

Human Genetic Disorders

You Can Observe a Lot By Just Watching. Wayne J. Morgan, MD, CM

Cystic Fibrosis. Jennifer McDaniel, BS, RRT-NPS

Diagnostic challenges after NBS for CF

PULMONARY SURFACTANT, ALPHA 1 ANTITRYPSIN INHIBITOR DEFICIENCY, AND CYSTIC FIBROSIS DR. NABIL BASHIR BIOCHEMISTRY/RESPIRATORY SYSTEM

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

E-BOOK # PANCREATIC ENZYMES FOR CYSTIC FIBROSIS ARCHIVE

Oral Cystic Fibrosis Modulators

Supplementary appendix

Thorax Online First, published on May 7, 2009 as /thx

Enabling CF Therapeutic Development

Clinical Trials for Rare Diseases in CDER

Tay Sachs, Cystic Fibrosis, Sickle Cell Anemia and PKU. Tay Sachs Disease (also called Hexosaminidase deficiency)

Lesson Overview. Human Genetic Disorders. Lesson Overview Human Genetic Disorders

Cystic Fibrosis Update

Genotypes and Phenotypes in Cystic Fibrosis and Cystic Fibrosis Transmembrane Regulator Related Disorders

High morbidity and mortality in cystic fibrosis patients compound heterozygous for 3905insT and DF508

Pancreatitis in Cystic Fibrosis and CFTR-Related Disorder

Cystic Fibrosis a) Diagnostic Dilemmas b) The New Problems. Dr Mark Rosenthal Royal Brompton Hospital London

Pass the salt please!

Human Genetic Disorders. Lesson Overview. Lesson Overview Human Genetic Disorders

C ystic fibrosis (CF) affects multiple organs, including the

Intestinal current measurement for diagnostic classification of patients with questionable cystic fibrosis: validation and reference data

Symposium: Genetic aspects of male (in)fertility

What is Cystic Fibrosis? CYSTIC FIBROSIS. Genetics of CF

Proteins. Length of protein varies from thousands of amino acids to only a few insulin only 51 amino acids

The Deciphering Development Disorders (DDD) project: What a genomic approach can achieve

Class Update with New Drug Evaluation: Oral Cystic Fibrosis Modulators

Genetic diseases. - chromosomal disorders (aneuploidy) - mitochondrial inherited diseases (female lineage transmission)

CLINICAL MEDICAL POLICY

ivacaftor 150mg film-coated tablets (Kalydeco ) SMC No. (1193/16) Vertex Pharmaceuticals (Europe) Ltd

Cystic fibrosis and survival to 40 years: a study of cystic fibrosis transmembrane conductance regulator function

Corporate Medical Policy

A treatment option for patients with CF who have responsive mutations

T he cystic fibrosis transmembrane conductance regulator

Guided Notes: Simple Genetics

Cystic fibrosis and infertility caused by congenital bilateral absence of the vas deferens and related clinical entities

Proposal form for the evaluation of a genetic test for NHS Service Gene Dossier

HIMANSHU SHARMA. POSITION APPLIED FOR Postdoctoral Fellow

An Effective Model to Communicate Complex Genetic Information to Families and Health Care Providers

PART VI Summary of the RMP

Cystic fibrosis: hitting the target

CYSTIC FIBROSIS Risk Factors Epidemiology Pathogenesis Defective protein synthesis (10%) Abnormal protein folding, processing & trafficking

Transcription:

THE ROLE OF CFTR MUTATIONS IN CAUSING CYSTIC FIBROSIS (CF) Vertex Pharmaceuticals Incorporated, 50 Northern Avenue, Boston, MA 02210. Vertex and the Vertex triangle logo are registered trademarks for Vertex Pharmaceuticals Incorporated. 2018 Vertex Pharmaceuticals Incorporated VXR-US-20-02038 01/2018 1 2018 Vertex Pharmaceuticals Incorporated

Program objectives Increase your knowledge of: The importance of CFTR protein regulation in the body How CFTR mutations are inherited, and how they affect CFTR protein quantity and/or function and total CFTR activity The links between CFTR mutations, CFTR activity, and CF disease development CFTR, cystic fibrosis transmembrane conductance regulator. 2 2018 Vertex Pharmaceuticals Incorporated

CFTR PROTEINS IN NORMAL CELLS 3 2018 Vertex Pharmaceuticals Incorporated

CFTR proteins: An important regulator of fluid and ion balance in organs throughout the body CFTR proteins are found on epithelial cell surfaces in organs throughout the body 1-4 Normally, CFTR protein channels transport ions, such as chloride and bicarbonate, through the epithelial cell surface in these organs 1-4 Maintaining water and salt balance at the epithelial cell surface requires an adequate quantity and function of CFTR proteins 5 Total CFTR activity can be defined as total ion transport mediated by CFTR protein channels at the cell surface. It is dependent on CFTR protein quantity and function 6,7 CFTR quantity X CFTR function Channel-open probability Conductance X = Total CFTR activity References: 1. Zielenski J. Respiration. 2000;67(2):117 133. 2. O Sullivan BP, Freedman SD. Lancet. 2009;373(9678):1891-1904. 3. MacDonald KD et al. Pediatr Drugs. 2007;9(1):1-10. 4. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 5. Elborn JS. Lancet. 2016;388(10059):2519-2531. 6. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 7. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 4 2018 Vertex Pharmaceuticals Incorporated

CFTR proteins reach the membrane through a multi-step process X CFTR protein function and breakdown X X X CFTR protein trafficking (delivery to the cell surface) CFTR protein synthesis CFTR mutations may affect different steps of this process to reduce CFTR quantity and/or function and reduce total CFTR protein activity 1,2 X X CFTR gene expression References: 1. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 2. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 5 2018 Vertex Pharmaceuticals Incorporated

CFTR MUTATIONS AND THEIR EFFECTS ON CFTR PROTEIN ACTIVITY 6 2018 Vertex Pharmaceuticals Incorporated

CFTR mutations are inherited genetically If a person inherits 2 copies of a disease-causing CFTR mutation (one from each parent), CFTR protein dysfunction can occur 1 CFTR protein dysfunction impairs cellular chloride transport CF disease can be the result Reference: 1. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 7 2018 Vertex Pharmaceuticals Incorporated

CFTR mutations may affect CFTR quantity and/or function, reducing total CFTR activity Spectrum of phenotypes associated with total CFTR activity 1 People with 2 CFTR mutations resulting in loss of CFTR activity generally have a CF phenotype, which may include 1,2 Elevated sweat chloride (>60 mmol/l) Pancreatic insufficiency CBAVD Lung function decline over time Pseudomonas aeruginosa colonization Certain CFTR mutations result in some CFTR activity 1,2 Other CFTR mutations result in little to no CFTR activity 1,2 Adapted with permission from Castellani and Assael. CBAVD, congenital bilateral absence of vas deferens. References: 1. Castellani C, Assael BM. Cell Mol Life Sci. 2017;74:129-140. 2. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 8 2018 Vertex Pharmaceuticals Incorporated

Different CFTR mutations produce different effects on CFTR protein quantity and function CFTR mutations are grouped into classes according to their effects on CFTR protein synthesis, trafficking, or function 1-3 CFTR quantity X CFTR function Channel-open probability X = Conductance Total CFTR activity Defective synthesis (Class I) Defective processing and trafficking (Class II) Defective gating (Class III) Defective conductance (Class IV) Decreased splicing (Class V) Decreased protein stability (Class VI) Classes I-V comprise the 25 most common mutations in the US CF patient population 4 References: 1. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 9 2018 Vertex Pharmaceuticals Incorporated

Examples of CFTR mutations that result in defective biosynthesis of the CFTR protein CFTR quantity CFTR function Total CFTR activity Defective synthesis yields no functional CFTR protein 1-3 Channel-open Conductance: X probability: X = Little to none Little to none Little to none 1-3 An absence of CFTR protein regardless of function since few to no CFTR proteins reach the surface... results in little to no total CFTR activity Examples (Class I) Type 4 US prevalence (%) 5 G542X Nonsense 4.7 1717-1G A Splice defect 1.6 3659delC Frameshift 0.7 References: 1. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 10 2018 Vertex Pharmaceuticals Incorporated

Examples of CFTR mutations that result in defective processing and trafficking of the CFTR protein CFTR quantity CFTR function Total CFTR activity Defective processing and trafficking results in few CFTR proteins at cell surface 1-3 Channel-open Conductance: X probability: X = Little to none Little to none Little to none 1-3 Significantly reduced CFTR protein regardless of function since few to no CFTR proteins reach the surface... results in little to no total CFTR activity Examples (Class II) Type 4 US prevalence (%) 5 F508del Amino acid deletion 86.4 a N1303K Missense 2.4 a Homozygous and heterozygous. References: 1. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 2. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 11 2018 Vertex Pharmaceuticals Incorporated

Example of CFTR mutations that reduce channel-open probability in the CFTR protein CFTR quantity CFTR function Total CFTR activity Normal Defective channel Conductance: X gating at cell X = Normal membrane 1-3 Little to none 1-3 Although CFTR protein quantity may be normal function is severely reduced due to decreased channel-open probability... and results in little to no total CFTR activity Examples (Class III) Type 4 US prevalence (%) 5 G551D Missense 4.4 References: 1. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 12 2018 Vertex Pharmaceuticals Incorporated

Example of CFTR mutations that result in a CFTR protein with defective conductance CFTR quantity CFTR function Total CFTR activity Normal Channelopen probability: Normal X X = Conductance: Reduced 1-3 Some 1-3 Although CFTR protein quantity may be normal function is reduced due to decreased conductance... and results in some total CFTR activity Examples (Class IV) Type 4 US prevalence (%) 5 R117H Missense 3.0 References: 1. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 13 2018 Vertex Pharmaceuticals Incorporated

Examples of CFTR mutations that result in some functional CFTR at the cell surface CFTR quantity CFTR function Total CFTR activity Reduced 1-3 Channel-open Conductance: X probability: X = Little to none Little to none Some 1-3 CFTR protein quantity is reduced even though CFTR function is not impaired... and results in some total CFTR activity Examples (Class V) Type 4 US prevalence (%) 5 3849+10kbC T Splice defect 3.0 A455E Missense 0.6 References: 1. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 2. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 3. Zielenski J. Respiration. 2000;67(2):117 133. 4. Ogino S et al. J Mol Diagn. 2007;9(1):1-6. 5. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 14 2018 Vertex Pharmaceuticals Incorporated

THE IMPACT OF REDUCED CFTR ACTIVITY 15 2018 Vertex Pharmaceuticals Incorporated

Both CFTR mutations play a role in determining phenotype and disease severity As CFTR activity declines, CF development becomes more likely 1 100% Total CFTR activity No CF disease Normal individuals and CF carriers CFTR-related disorder Clinical entities associated with CFTR dysfunction that may not fulfill diagnostic criteria for CF CFTR genotype affects sweat chloride concentration, an indicator of underlying CFTR activity and a principle diagnostic marker for CF 1 0% Cystic fibrosis Mutation 1 (Total CFTR activity) Mutation 2 (Total CFTR activity) Normal Normal Normal Some Some Normal Some Little to none Some Little to none Little to none Little to none Normal: No CF-causing mutation. Some: Classes IV-VI. Little to none: Classes I-III. Adapted with permission from Zielenski. Reference: 1. Zielenski J. Respiration. 2000;67(2):117-133. 16 2018 Vertex Pharmaceuticals Incorporated

Summary CFTR protein is an important cellular regulator in organs throughout the body 1,2 CFTR mutations, which are acquired genetically, decrease CFTR protein function and/or quantity to reduce total CFTR activity Loss of CFTR protein activity is the underlying cause of CF Different types of CFTR mutations vary in their effects on CFTR protein quantity and/or function, because they affect CFTR protein formation in different ways 2,3 Both CFTR mutations play a role in determining phenotype or disease severity 4 References: 1. Boyle MP, De Boeck K. Lancet Rep Med. 2013;1:158-163. 2. Derichs N. Eur Respir Rev. 2013;22(127):58-65. 3. Cystic Fibrosis Foundation. Patient Registry Annual Data Report 2016. Bethesda, MD. 2017 Cystic Fibrosis Foundation. 4. Zielenski J. Respiration. 2000;67(2):117 133. 17 2018 Vertex Pharmaceuticals Incorporated